5-alpha Reductase Inhibitors

• 

  Subject Areas on Research

  • 5-α reductase inhibitors and prostate cancer prevention: where do we turn now? 
  • 5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. 
  • 6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase. 
  • 6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase. 
  • Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. 
  • Androgens and masculinization of genitalia in the spotted hyaena (Crocuta crocuta). 2. Effects of prenatal anti-androgens. 
  • Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. 
  • Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy. 
  • Chemoprevention of prostate cancer. 
  • Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. 
  • Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. 
  • Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. 
  • Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. 
  • Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. 
  • Evaluation and treatment of male and female pattern hair loss. 
  • Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. 
  • Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. 
  • Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. 
  • Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. 
  • Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. 
  • Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1). 
  • Prostate. III--A structural feature characteristic of the rat prostate 5 alpha-reductase active site. 
  • Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. 
  • Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. 
  • The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. 
  • The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.